Intravitreal adalimumab may be successful when systemic therapy fails

COPENHAGEN — Intravitreal adalimumab may be an “attractive” off-label option for treating breakthrough uveitis in patients on systemic adalimumab therapy, according to Rola Hamam, MD. At the Euretina meeting, Hamam presented a retrospective review of 13 episodes of treatment failure in seven eyes of four patients treated with intravitreal 1.5 mg adalimumab after treatment failure with 40 mg subcutaneous adalimumab.